SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Filed Against Nektar Therapeutics (NKTR)GlobeNewsWire • 04/23/26
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRNewsfile Corp • 04/23/26
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Enrollment Violations: Levi & KorsinskyPRNewsWire • 04/22/26
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud LawsuitPRNewsWire • 04/22/26
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRGlobeNewsWire • 04/22/26
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTRGlobeNewsWire • 04/21/26
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law FirmPRNewsWire • 04/21/26
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRNewsfile Corp • 04/21/26
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage DevelopmentSeeking Alpha • 04/20/26
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Institutional Shareholders: Levi & KorsinskyGlobeNewsWire • 04/20/26
Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata TranscriptSeeking Alpha • 04/20/26
Nektar Therapeutics Adds To Its 129% Two-Month Run With Alopecia NewsInvestors Business Daily • 04/20/26
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with RezpegaldesleukinPRNewsWire • 04/20/26
ROSEN, TRUSTED TRIAL COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRNewsfile Corp • 04/20/26
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026PRNewsWire • 04/19/26
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRGlobeNewsWire • 04/19/26
ROSEN, A HIGHLY RANKED NATIONAL FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRNewsfile Corp • 04/16/26
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTRPRNewsWire • 04/16/26
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallStPRNewsWire • 04/16/26